Celularity regained compliance with Nasdaq’s minimum bid-price and minimum market-value requirements, closing both matters. The company’s delayed periodic reports remain an unresolved compliance issue, and Celularity says it continues work to complete those filings and restore compliance with Nasdaq’s reporting requirement.
Key Highlights
- Nasdaq’s Listing Qualifications Staff sent written notifications on September 11 confirming the two compliance restorations.
- K. Harold Fletcher signed the company’s report on September 14 as chief legal and strategy officer.
- Celularity continues efforts to complete delayed periodic reports and regain compliance with Nasdaq’s reporting requirement.
Celularity Inc. (NASDAQ: CELU) has regained compliance with Nasdaq’s minimum bid-price requirement and its minimum market-value requirement for listed securities. The two listing matters are now closed, while Celularity continues work on a separate periodic-reporting deficiency.
Written notifications reached Celularity on September 11 from the Listing Qualifications Staff of Nasdaq. Celularity’s report was signed on September 14 by K. Harold Fletcher, chief legal and strategy officer. The document was executed on behalf of Celularity under the requirements of the Securities Exchange Act of 1934.
Delayed Reports Remain Outstanding
Celularity said it continues working to complete its delayed reports and restore compliance with Nasdaq’s periodic-reporting standard.
FAQs
Q: What Nasdaq requirements did Celularity regain compliance with?
A: Celularity restored compliance with Nasdaq’s minimum bid-price requirement and minimum market-value requirement for listed securities. Nasdaq confirmed that both matters are closed.
Q: What compliance issue remains for CELU?
A: Celularity still has an outstanding deficiency tied to delayed periodic reports. The company continues working to complete those reports and regain compliance with Nasdaq’s periodic-reporting requirement.
Q: When did Nasdaq confirm Celularity’s compliance?
A: Nasdaq’s Listing Qualifications Staff sent written notifications to Celularity on September 11. The notifications confirmed restoration of compliance with the two listing requirements.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.